Remdesivir, Favipiravir i Sinefungina, tres nucleòsids amb potencial activitat antiviral contra SARS-CoV-2 by Pruñonosa Martin, Laia
 
Tutor/s 
Dr. Jordi Robles Brau 
Departament de Química Inorgànica i 
Orgànica. Secció de Química Orgànica. 
 
 
Treball Final de Grau 
Remdesivir, Favipiravir and Sinefungin, three nucleosidic 
products with potential antiviral properties against SARS-CoV-2 
Remdesivir, Favipiravir i Sinefungina, tres nucleòsids amb 
potencial activitat antiviral contra SARS-CoV-2 
Laia Pruñonosa Martin 














Res a la vida s’ha de témer; només s’ha 
d’entendre. Ara és el moment d’entendre més,    




Vull dedicar el treball especialment a la meva família, Montse, Josep i Mireia pel suport, el 
recolzament i els ànims del dia a dia. 
Dedicar-lo també al meu tutor, Jordi Robles, per fer que el treball a distància fos molt més 






Remdesivir, Favipiravir and Sinefungin, three nucleosidic products with potential antiviral activity against SARS-CoV-2  1 
 
CONTENTS 
1. SUMMARY 3 
2. RESUM 5 
3. INTRODUCTION 7 
3.1. World’s critical and current situation 7 
3.2. SARS-CoV-2 9 
    3.2.1. Life cycle of SARS-CoV-2 9 
    3.2.2. Molecular biology and viral structure 10 
3.2.2.1. Structural proteins  10 
3.2.2.2. Non-structural proteins  11 
3.3. Discovery and development of new antivirals against SARS-CoV-2 12 
    3.3.1. RNA-dependent RNA polymerase (RdRp) inhibitors 14 
    3.3.2. 2’-O-RNA methyltransferases (MTAse) inhibitors 16 
4. OBJECTIVES  17 
5. METHODS 17 
6. BIBLIOGRAPHIC ABSTRACT AND DISCUSSION 19 
6.1. Remdesivir   20 
6.1.1. . Prodrug development    20 
6.1.2. . Synthesis of Remdesivir    23 
6.1.3. . Mode of action of Remdesivir    24 
6.1.4. . Therapeutic and pharmacological properties    26 
6.2. Favipiravir   27 
6.2.1. . Prodrug development 27 
6.2.2. . Synthesis of Favipiravir 28 
6.2.3. . Mode of action of Favipiravir 31 
6.2.4. . Therapeutic and pharmacological properties 31 
 
2 Pruñonosa Martin, Laia 
 
6.3. Sinefungin   32 
6.3.1. . Drug development       32 
6.3.2. . Synthesis of Sinefungin       32 
6.3.3. . Mode of action of Sinefungin       35 
6.3.4. . Therapeutic and pharmacological properties       35 
7. CONCLUSIONS  37 
8. REFERENCES AND NOTES  39 
9. ACRONYMS AND ABBREVIATIONS 43 
 
Remdesivir, Favipiravir and Sinefungin, three nucleosidic products with potential antiviral activity against SARS-CoV-2  3 
 
1. SUMMARY 
In December 2019, an outbreak of pneumonia of unknown origin was reported in Wuhan, 
China. The causing agent was promptly recognised as a new coronavirus (CoV) titled as       
SARS-CoV-2. The accelerated set of scientific findings on SARS-CoV-2 provided in a record time 
a meaningful amount of potential drug targets. Current promising strategies to pharmacologically 
target SARS-CoV-2 are vaccines and repurposing drugs. Repurposing antivirals have the 
advantage of accelerated market approval because of the previously broad knowledge of the 
drug's behaviour in humans and the feasibility of combining the repurposed drugs with other ones 
to reach much more effective treatments. Nonetheless, more therapeutic trials are required to 
establish whether these drugs are indeed efficacious and safe against SARS-CoV-2. 
In this TFG report, through a previous analysis of the biology and activity of the virus, we will 
review three current potential antivirals against SARS-CoV-2: Remdesivir, Favipiravir and 
Sinefungin. Concretely, the chemical methodologies adopted for either development and 
synthesis, mode of biological action and therapeutic and pharmacological properties will be 
specifically treated for each antiviral.  
Keywords: Covid-19, SARS-CoV-2, antivirals, Remdesivir, Favipiravir, Sinefungin, drug 
repurposing. 
Remdesivir, Favipiravir and Sinefungin, three nucleosidic products with potential antiviral activity against SARS-CoV-2  5 
 
2. RESUM 
Al desembre de 2019 es va donar notícia d’un brot de pneumònia d'origen desconegut a 
Wuhan (Xina). L'agent causant va ser reconegut ràpidament com un nou coronavirus (CoV) 
denominat SARS-CoV-2. El progressiu abast de les troballes científiques sobre el SARS-CoV-2 
ha proporcionat en un temps rècord una quantitat significativa de possibles dianes terapèutiques. 
Actualment, les estratègies prometedores per actuar farmacològicament contra la SARS-CoV-2 
són les vacunes i la reutilització de fàrmacs. El reposicionament d’antivirals té com a avantatges 
una aprovació de comercialització més ràpida donat que es coneix àmpliament el comportament 
del fàrmac en els éssers humans i la possibilitat de combinar-los amb d’altres per aconseguir 
tractaments molt més eficaços. No obstant això, es segueixen requerint més assaigs clínics per 
establir si aquests fàrmacs són realment eficaços i segurs contra el SARS-CoV-2. 
En aquesta memòria de TFG, partint d'una anàlisi prèvia de la biologia i l'activitat del virus, 
es revisaran tres potencials antivirals actuals contra la SARS-CoV-2: el Remdesivir, el Favipiravir 
i la Sinefungina. Concretament, de forma específica per a cada antiviral, es tractaran les 
metodologies químiques tant de desenvolupament com de síntesi, el mode d'acció biològica i les 
propietats terapèutiques i farmacològiques.  
Paraules clau: Covid-19, SARS-CoV-2, antivirals, Remdesivir, Favipiravir, Sinefungina, 
antivirals, reposicionament de fàrmacs. 
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3. INTRODUCTION 
3.1. WORLD’S CURRENT AND CRITICAL SITUATION 
Due to the unpredictable Covid-19 pandemic, the world is currently in a state of uncertainty 
as Covid-19 has changed and stopped the world in just half a year. SARS-CoV-2, also known as 
2019-nCoV or Wuhan coronavirus, is the virus responsible for the outbreak and the respiratory 
disease caused by it is COVID-19. The symptoms of the SARS-CoV-2 infection are quite varied 
as it ranges from asymptomatic, to mild or severe with the possibility of death.1 Although the 
mortality rate is currently quite low, the virus has spread rapidly around the world due to the ease 
connection between countries. In the last six months, a large number of people died due to virus-
induced pneumonia and as a consequence of the global paralysis, the economy is in an unknown 
and prolonged situation with highly unfavourable consequences in both short and long term.2  
In December 2019, in Wuhan, China, an outbreak of pneumonia of unknown origin was 
reported. It was speculated that the first infected human caught the infection in a seafood market 
where wild animals were also traded in Wuhan City. After that happened, it was quickly identified 
as a new coronavirus (CoV). Since the virus started infecting in December, an unprecedented 
fast-spreading worldwide pandemic was stabilized in the globe. As we could observe since the 
virus arrived, the level of person-to-person transmission of CoV increased exponentially due to 
the modern world's traffic highways.3 
Coronavirus family members have been responsible for several outbreaks and deadly 
epidemics over the past decade (SARS 2002, MERS 2012).3 For this reason, and based on 
previous experience with other coronaviruses, China took strict measures while facing the new 
situation and several cities were isolated and confined in an attempt to prevent the spread of the 
pandemic. 
The origin of the virus is not completely clear but the scientific community says that the 
possible zoonotic transfer came from bats or pangolins.2 The spread of the virus that began in 
2019 is growing at an unprecedented rate. SARS-CoV-2 has travelled around the world and as a 
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consequence of that, the current situation is the following one with more than 80 million cases, 
more than one and a half million deaths and more than 60 million people recover. 
As we can prove in the last decade, the CoV family has attained to stay, whether one mutation 
or another. COVID-19 could either disappear or settle in the human population and reappear 
seasonally in future mutations through animal zoonosis. However, outbreaks of CoV and other 
viruses are likely to occur in the coming years, so scientific communities need to be prepared to 
combat an unpredictable situation like the current one. That is the reason why research groups 
recently started to study emerging variants of coronavirus because the more we learn about novel 
viruses, the better we can respond.1 
On the one hand, a short-term solution is needed to find a drug to treat the high number of 
seriously ill patients as an emergency solution due to the unstable situation. On the other hand, 
a long-term solution must be required for developing drugs to prevent and cure future coronavirus 
outbreaks. 1 
Since the beginning of the global pandemic, the scientific community has been fully involved 
in research within a wide range of antivirals to combat coronavirus.4 The current exceptional 
situation is testing scientists due to the urgent need for coronavirus treatment or prevention.5 
Thanks to technology's progression, the scientific community could react more straightforward to 
the situation as information about the biology and spread of the virus was quickly shared and 
available for scientists. As a result of the global pandemic, research is additionally being done to 
combat outbreaks of possible future mutations in CoV or other viruses. 
Moreover, more and more companies are getting involved in the global pandemic because of 
the demand for new medicines to treat COVID-19. There are several potential options to 
pharmacologically fight COVID-19 as vaccines, natural medicines, small-molecule drugs, 
monoclonal antibodies and drug repurposing.1 The timelines for the development of a vaccine 
could be faster rather than developing a de novo small-molecule drug but due to the challenging 
situation, it is required a quick solution in a short period of time. Drug repurposing6 existing 
antiviral agents seems to be one of the best ways to fight COVID-19 because of the already 
immense knowledge of the drug's behaviour in humans. That is an overwhelming advantage as 
those antivirals were previously clinically evaluated and due to the demand for a short-term 
solution, it seems a potential way of success.4 
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3.2. SARS-COV-2 
SARS-CoV-2 is a type of coronavirus that causes COVID-19 disease and can infect both 
humans and animals. The coronavirus family can be classified into alpha, beta, gamma, and delta 
classes. Specifically, SARS-CoV-2 is a β-coronavirus and is believed to be derived from bats that 
are asymptomatic because they don’t show signs of disease.7 The β-coronavirus had already 
caused previous outbreaks of severe acute respiratory syndromes, SARS, such as SARS-CoV in 
2002 in China and MERS-CoV in 2012.3 
Similar to earlier SARS-CoV and MERS-CoV, SARS-CoV-2 first infects the alveolar epithelial 
cells of the lungs and could lead to severe pneumonia with a mortality rate of 2% to 5%. Moreover, 
the virus can affect different organs such as the heart, liver, central nervous system, kidney and 
gastrointestinal tract, originating organ failure.3 
The scientific community has demonstrated that there are some common clinical 
manifestations in patients. The main symptoms of infected people are fever, followed by cough 
and a loss or change to your sense of smell or taste. Other symptoms related to Covid-19 are 
dyspnoea, myalgia, headache and diarrhoea but not as common as the three main ones.2  
3.2.1. Life cycle of SARS-CoV-2 
The principal tracts that SARS-CoV-2 infects are the respiratory and the gastrointestinal ones. 
The virus enters the cell within the interaction of the viral protein S and the ACE2 cell receptor. 
Following entry, viral RNA is released from the endosome and translated into viral replicase 
polyproteins, which are cleaved into functional proteins, such as RdRp, N protein or helicase, 
thanks to viral proteases. After the viral protease cleavage, the viral genome replication is set up 
by the viral replication complex that includes RdRp, helicase and protein N. Once the replication 
finishes, viral nucleocapsids from the packaged viral genomes and translated viral structures are 
freed from the cell through exocytosis.8,9  
Potential targets and mechanisms of action against SARS-CoV-2 have been postulated such 
as blocking the interaction between the virus and the membrane receptors of host cells through 
the use of antibodies, inhibiting the processing of polyproteins into viral proteins by protease, and 
inhibiting viral RNA replication via nucleoside/nucleotide analogues like Remdesivir.8,10  
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3.2.2. Molecular biology and viral structure 
The β-coronaviruses are pathogenic to humans and contain a single-stranded RNA genome 
that is encapsulated by a membrane envelope (see Figure 1).3 Although the genome of the virus 
is quite large in size, it contains approximately 30,000 bases, encoding few proteins. On the one 
hand, there are structural proteins: the Spike protein (S), Membrane protein (M), Envelope protein 
(E) and Nucleocapsid protein (N) which are essential for the structure of a viral particle. The N 
protein holds the RNA genome, whereas the M, S and E proteins create the viral envelope. On 
the other hand, the viral genome also encodes 16-17 non-structural proteins (ns1 to ns17) such 
as 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), helicase (H) and       









3.2.2.1. Structural proteins 
The morphology of the virus is due to transmembrane S glycoproteins which form 
homotrimers that protrude from the viral surface creating the crown-shaped structure of the virus. 
The S protein is anchored to the membrane and acts as an intermediary for virus entry into host 
cells by first binding to a host receptor and then fusing the membranes of the host cell and the 
viral one.3 
The affinity between the viral receptor-binding domain (RBD) and the host receptor in the first 
binding is what mainly determines which host is susceptible to SARS-CoV-2 infection.            
SARS-CoV-2 uses the receptor angiotensin-converting enzyme 2 (ACE2), an exopeptidase 
expressed on epithelial cells of the respiratory system, and the transmembrane serine        
protease 2 (TMPRSS2) to facilitate cells entry.3 
Figure 1. Structure of SARS-CoV-2 and some of its molecular protein targets (image taken from Dömling, A. et al, ref. 1). 
Remdesivir, Favipiravir and Sinefungin, three nucleosidic products with potential antiviral activity against SARS-CoV-2  11 
 
After host cell entry, the viral RNA is released for viral RNA replication and translation of virus 
polyproteins that finally shift into mature effector proteins via virus proteases. The S protein 
interaction with ACE2 on host cells membrane launches viral infection. 
Earlier researches employed to prevent binding SARS-CoV to its host cell receptor ACE2 
might be relevant since SARS-CoV-2 also uses ACE2 as a way to get into the cell. The information 
about the viral structure and biology is remarkably useful to determine the antivirals that can 
interact with the virus and inhibit it. There are multiple mechanisms identified that could be useful 
for the pharmacological intervention in the infection and replication processes of the virus due to 
the ability to block viral host cell entry. For instance, inhibiting ACE2 may constitute a 
pharmacological target to avoid SARS-CoV-2 entry into the host cell. 
The scientific community discovered some capable strategies for interrupting protein S 
binding with receptor ACE2 which could have significant therapeutic value. The affinity of      
ACE2-binding has been demonstrated to be one of the most important determinants of          
SARS-CoV infectivity. It is known that the binding affinity of the protein S of SARS-CoV-2 to ACE2 
is 10 or 20 times greater than protein S of earlier SARS-CoV, which may contribute to higher 
contagiousness of SARS-CoV-2 compared to the elder SARS-CoV. The affinity of ACE2-binding 
has been demonstrated to be one of the most important determinants of SARS-CoV infectivity. 
Pharmacologists proved that a single N501T mutation in the SARS-CoV-2 Spike protein may 
significantly intensify the binding affinity between 2019-nCoV RBD and human ACE2.9 
Considering that Spike protein of SARS mutated over the pandemic of 2002-2004 to better bind 
human cell-surface receptors, this is a situation that can be probably repeated in the future.11 
Mutations in the S protein are the ones causing zoonosis, and as a result, not all of them will 
lead to their union to ACE2. Hence, antiviral drugs focused on the current interaction between 
protein S and ACE2 might not be useful for future CoVs.1 
3.2.2.2. Non-structural proteins 
Although SARS-CoV and SARS-CoV-2 are not identical, there are some conserved proteins 
associated with both of them, including 3CLpro, also named MPro, and RdRp which share over 
95% of similarity between the two viruses. 3CLpro and PLpro are viral proteases which 
decompose viral polyproteins into functional units within host cells that are finally assembled into 
new viruses. RdRp is essential for replicating the viral genome within the host cell. 
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The 3CLpro is a cysteine protease that cleaves and processes viral polyproteins. The majority 
of 3CLpro inhibitors are covalent in nature, binding to the active-site cysteine. Their selectivity 
towards other potential objectives in the human body has not been proved yet. Even if antivirals 
cannot be quickly developed for the current situation, their development is highly supported to be 
prepared for probable future CoV outbreaks. In fact, computational approaches have been 
published to offer approved drugs potentially binding to 3CLpro. Viral protease inhibitors such as 
Ritonavir/Lopinavir that were used to inhibit diseases like Ebola virus or HIV, were also considered 
candidate drugs against SARS-CoV-2.  
Another attractive antiviral drug target that is essential for CoV replication is PLpro. The 
structure, function and inhibition of SARS-CoV-2 PLpro have been widely analysed. Although the 
main function of PLpro and 3CLpro is to process the viral polyprotein in a coordinated way, PLpro 
has an additional function of removing ubiquitin and ISG15 from host-cell proteins to help CoV to 
evade natural immune responses of the host cell. Accordingly, it was newly discussed that 
targeting PLpro with antiviral drugs could be an improvement not only for inhibiting viral replication 
but also inhibiting the dysregulation of signalling cascades in infected cells that might end to cell 
death of uninfected cells that are surrounding.1  
The RdRp enzyme enables the viral genome to be transcribed into new RNA copies 
employing the host cell's engine. Inhibitors of RdRp are being analysed as a new strategy to fight 
against viral infections, that's why viral biology and chemistry have been recently reviewed. Due 
to the similarity of sequence identity between RdRp proteins of SARS-CoV-2 and SARS-CoV, 
inhibitors of RNA polymerase are likely agents to combat Covid-19. Both of them share 96% of 
sequence identity. Promising RdRp inhibitors of SARS-CoV-2 are Remdesivir and Favipiravir 
which were used previously for treatments of Ebola and influenza pandemic respectively.1 
3.3. DISCOVERY AND DEVELOPMENT OF ANTIVIRALS AGAINST SARS-COV-2 
Antiviral drugs are a class of medicine used for treating viral infections. The majority of 
antivirals target particular viruses, while a broad-spectrum antiviral is efficacious against a large-
scale variety of viruses. Before creating the antiviral, it is required to identify the viral proteins, or 
parts of proteins, that can be disabled. The targets generally need to be as unlike any proteins or 
parts of proteins in humans as possible, to reduce the possibility of side effects. Moreover, the 
targets need to be common over many viral strains within the same family, so then a single drug 
will have more extended effectiveness.  
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Once targets are distinguished, candidate drugs can be elected, either from known drugs that 
have suitable effects or by creating the candidate one from the beginning at a molecular level with 
a computer-aided design program. Then, the target proteins can be developed in laboratories for 
testing with diverse treatments by injecting the gene that synthesizes the target protein within 
bacteria cells. Following that, cells are cultivated for massive production of the protein, so then 
those proteins can be exposed to different treatment candidates and finally be evaluated. Utilizing 
rapid screening technologies, drugs can be analysed, and possible side effects could be 
identified. 
Potential target drugs are easier to discover and develop if the viral structure and biology is 
deeply reviewed. For the arrangement of the replication and transcription processes, there is an 
enormous network described between the non-structural proteins of SARS-CoV-2. Likewise, viral 
particle assembly requires coordinated interaction between structural S, N, M and E proteins.1  
All these interactions could be interesting targets for future CoV because nowadays more 
structural information is required. As soon as structural targets are determined, leading structural 
inhibitors will be provided.1 
Developing a novel drug is a lengthy process that requires many competencies from the 
scientific community, such as biologists, pharmacologists and chemists. In fact, it is a highly priced 
development and most of the compound candidates fail along the way (one of every ten 
candidates). 
The drug development process incorporates five different steps. The first step consists of the 
discovery and research for a new drug in the laboratory. Next step is the preclinical research 
where drugs undergo laboratory and animal testing to solve basic questions about safety. 
Following that, drugs are tested on people to make sure they are safe and effective during clinical 
research. 
Four-phase studies are needed for drug approval and they aim to perform clinical research 
and study drug’s safety on humans: 
∙ In phase 1, the study involves between 20 and 100 healthy volunteers or people with the 
disease to analyse the drug's safety and dosage. In phase 1, approximately 70% of drugs move 
to phase 2.  
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∙ In phase 2, the study includes up to several hundred people with the disease to define the 
efficacy and side effects. In the second phase, around 33% of drugs move to the next phase.  
∙ The longest phase is the third one due to the study's length around 1 to 4 years. In phase 3, 
the number of participants goes from 300 to 3000 volunteers who have the disease, and the 
objective is to determine the efficacy and monitoring of adverse reactions. In that phase, nearly 
25-30% of drugs move to the last phase. 
∙ In the last phase, several thousand volunteers who have the disease participate to define 
the safety and efficacy of the drug. 
Later, regulatory authorities (European Medicines Agency - EMA, Agencia Española de 
Medicamentos y Productos Sanitarios – AEMP, USA Food and Drugs Agency Administration – 
FDA) wholly examine all of the submitted data associated with the drug and decide to approve it 
or not.  
3.3.1. RNA-dependent RNA polymerase (RdRp) inhibitors 
Remdesivir (1) and Favipiravir (2) are inhibitors related to replication, membrane fusion and 
assembly of SARS-CoV-2. Remdesivir, formally known as GS-5734, is a monophosphate prodrug 
that metabolizes to an active C-adenosine nucleoside triphosphate analogue.5 Remdesivir (see 
Figure 2) was discovered while screening process against RNA viruses. That small-molecule 
adenine nucleotide analogue antiviral drug has demonstrated earlier effectiveness against Ebola 
virus in rhesus monkeys.12 Also, Remdesivir has proved antiviral activity against other single-
stranded RNA viruses such as MERS-CoV and earlier SARS-CoV. Remdesivir is a prodrug that 
is metabolized into its active triphosphate form and interferes with the activity of viral                   
RNA-dependent RNA polymerase (RdRp), pointing to inhibition of viral RNA synthesis. That 
prodrug, which has to be administrated intravenously, acts directly in the first steps of infection 
and diminishes the viral RNA levels in a dose-dependent way. In recent studies, some 
mechanisms of action of that prodrug have been proved in vitro for Ebola virus, MERS- CoV and 
earlier SARS-CoV. Experiments on SARS-CoV-2 infecting cells such as simian Vero E6 cells or 
human liver cancer cells, which are sensitive to SARS-CoV-2 infection, were efficiently inhibited 
by Remdesivir.13 Besides, the prophylactic and therapeutic effectiveness of Remdesivir has been 
proved lately in rhesus monkeys against MERS-CoV infection.3 











Favipiravir (see Figure 3), chemically known as 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, 
is an oral guanine analogue developed in Japan by Toyama Chemical. The antiviral was 
discovered throughout phenotypic screening against the influenza virus. Favipiravir selectively 
and potently inhibits RdRp of RNA viruses and causes lethal RNA transversion mutations, 
whereby forming a nonviable virus phenotype.14 This drug undergoes a phosphoribosylation in 
the cells to be transformed into an active form, known as Favipiravir-RTP, which is identified as 
the substrate by RdRp that inhibits the enzyme activity. As the RdRp catalytic domain is 
conserved in various sorts of RNA viruses, this mechanism allows a wide antiviral spectrum for 
Favipiravir.15 That drug was reported to inhibit the replication of multiple types of RNA viruses, 
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3.3.2. 2’-O-RNA methyltransferases (MTase) inhibitors 
Nucleoside derivatives that combine a nucleoside, mostly uridine or adenosine, with amino 
acids, lipids, peptides or glycosides, are popular secondary metabolites of wide structural variety. 
Many of them, isolated from bacteria, show diverse biological activities, hence they have been 
repeatedly used in the design and development of various antitumors, antibiotics and antivirals.16 
MTase is a likely target for antiviral therapy because is crucial for the RNA cap formation, a 
fundamental process for viral RNA stability. This MTase function is associated with the nsp16 
protein, which requires nsp10 as a cofactor for its satisfactory activity.17 
Sinefungin (3) (see Figure 4), also known as adenosine-ornithine, which was discovered in 
1971 from Streptomyces griseolus was initially identified as an antibiotic but later on, it was 
recognised as an antimalarial and antifungal.18 Sinefungin was first ruled out due to its low cell 
penetrability and toxicity in humans. Most likely due to its structural resemblance to                            
S-adenosylmethionine (SAM), its activity is due to the inhibition of 2'-O-RNA methyltransferases 
(MTase). In fact, that is the main reason why it has stirred interest as an antiviral, as MTase is a 














The aim of this project was to review the recent bibliography of drugs that could interact with 
SARS-CoV-2 and inhibit the virus. Remdesivir, Favipiravir and Sinefungin were chosen as 
potential drugs of SARS-CoV-2 which have revealed likely antiviral properties against 
coronaviruses.  
The bibliographic research focused on the present state of knowledge of the properties, 
structure-activity studies, synthetic routes and the antiviral potential of these three drugs. 
Furthermore, a secondary purpose of this project was also to analyse the current chemistry's 
role in the current global pandemic. 
5. METHODS 
The bibliographic research has been possible by using various scientific databases such as 
SciFinder, Reaxys, Web of Science, Mendeley, Science Direct, PubMed and PubChem to 
contrast papers and information. 
Searching keywords like Covid-19, SARS-CoV-2, Remdesivir, Favipiravir or Sinefungin, it has 
been achievable to obtain satisfactory results for the research. 
Since the beginning of the research, SciFinder and Web of Science were the most helpful 
database by searching keywords like Covid-19, SARS-CoV-2 and antivirals to get global 
information of the theme. The compilation of general information included approximately twenty 
papers and was mostly related to the world's current situation and the biology, life cycle and viral 
activity of SARS-CoV-2. Once general research was fulfilled, specific research of antivirals and 
drug repurposing was done by using databases like SciFinder, Reaxys, Science Direct, PubMed 
18 Pruñonosa Martin, Laia 
 
and PubChem. The compilation of approximately 30 papers for specific research was essential 
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6. BIBLIOGRAPHIC ABSTRACT AND DISCUSSION 
The discovery and development of new drugs require a long period of research and that is 
the reason why it is not a short-term solution for the current global pandemic. However, the reuse 
of drugs (drug repurposing)6 previously used in other diseases seems to be one of the possible 
short-term solutions to fight the coronavirus as vaccination is a solution that requires clinical 
approval and takes normally a longer time to obtain.20 
The extraordinary challenge for the scientific community during the current global public 
health crisis has made them rush because of the necessity of a vaccine. After conducting the final 
efficacy analysis in the phase 3 study, the Pfizer vaccine met all of the study's primary efficacy 
endpoints and seems to be safe and effective. Since the FDA's approval, the USA and UK started 
in early December the massive vaccination with the Pfizer vaccine, which primary efficacy 
analysis demonstrates to be 95% effective against SARS-CoV-2.21 EMA have recently approved 
Pfizer’s and Moderna’s vaccines to be administered in Europe, and it is expected that other 
(Oxford-Astra Zeneca, Sinopharm) will be also validated soon. 
Although other vaccines and antibodies targeting SARS-CoV-2 are under study, these still 
need a rigorous evaluation of efficacy and safety. Hence, drug therapy is possibly the unique 
practicable approach for a hurried response to the pandemic.22 
Despite their high species variety, coronaviruses share key genomic components that are 
fundamental for the design of therapeutic targets. Due to the similarity of different coronaviruses, 
some drugs such as Remdesivir and Ritonavir/Lopinavir that were used to treat diseases like 
Ebola virus or HIV, constitute candidate drugs against SARS-CoV-2 and are now investigated for 
their therapeutic efficacy in COVID-19 patients.3  
Drugs that have broad-spectrum activity against an ample range of coronaviruses and other 
viruses are the ones targeting either nucleosides or nucleotides and/or viral nucleic acids.23 This 
present work was devoted to summarize the information on three compounds that have been 
proposed to address this issue, Remdesivir (1), Favipiravir (2) and Sinefungin (3), depicted below 
in Figure 5. 
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6.1. REMDESIVIR 
Remdesivir (1, see Figure 5) is a prodrug of an adenosine analogue that can be incorporated 
in the nascent viral RNA chains and inhibit the RNA-dependent RNA polymerase, stopping the 
replication of the viral genome and result in premature termination.22 
Remdesivir is a wide-ranging antiviral medication developed by the pharmaceutical company 
Gilead Sciences and came out from a collaboration between Gilead, the U.S. Centers for Disease 
Control and Prevention and the U.S. Army Medical Research Institute of Infectious Diseases, 
intending to identify therapeutic agents for treating RNA-based viruses with global pandemic 
potential such as Ebola and other rising viruses.24 Later on, different clinical studies analysed its 
mechanism of action and its efficacy versus these viruses and they proved the broad-spectrum 
antiviral activity against RNA viruses. The unfavourable effect of Remdesivir is possible kidney 
damage due to the increment in transaminases.  
6.1.1. Prodrug development 
Structural modification of natural N-nucleosides (N-glycosides of pyrimidines and purines) on 
either the sugar or the base has driven to the development of diverse therapeutic agents, which 
involve antiviral and anticancer agents. This strategy has been often applied to identify additional 
agents with improved efficacy and safety over existing drugs and expand into novel therapeutic 
areas. 
Amongst all the likely alterations of the sugar moiety, the incorporation of a substituent at      
1'-position of the N-nucleosides has been unusually employed in drug design. This is slightly due 
to the chemical instability of the N-glycosidic bond provoked by namely dissociation of the base 
and the sugar at lower pH. Nonetheless, C-nucleoside, in which the sugar and the base are 
connected by the C-C bond, should be hydrolytically stable even with a 1'-substituent. As a result 
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of that, C-nucleoside could be an exemplary structure to investigate diverse 1'-substituted 
nucleosides for their therapeutic potential. A range of 1'-substituted C-nucleosides analogues of 
4-aza-7,9-dideazaadenosine (see Figure 6) were evaluated for their antiviral potential against 
various RNA viruses. These nucleoside inhibitors should be intracellularly transformed by kinases 
to the triphosphorylated nucleosides, which then operate as competitors of the natural nucleoside 
triphosphates in RNA synthesis.25  
 
A library of approximately 1000 different nucleoside and nucleoside phosphonate analogues 
was collected from over two decades of investigation across various antiviral programs and 
assayed in the research project. The 1'-methyl analogue was less active against Ebola virus and 
additionally presented a higher level of toxicity compared to the 1'-CN analogue which showed 
how small variations in the polarity and size of the 1'-substituent can impact the overall molecule.26 
The 1'-cyano-substituted adenine C-nucleoside ribose analogue (Nuc) presented antiviral activity 
against many RNA viruses. The Nuc requires intracellular anabolism to generate the active 
triphosphate metabolite (NTP) that interferes with the viral RdRp activity. Structurally, the 1'-cyano 
group granted potency and selectivity towards viral RNA polymerases.12 
Remdesivir (GS-5734) is the single Sp isomer of the 2-ethylbutyl L-alaninate 
phosphoramidate prodrug that efficiently avoided the rate-limiting first phosphorylation step of the 
Nuc. Remdesivir was shown to be more active than the parent non-phosphorylated nucleoside.12 
The initial phosphorylation step to synthesize the nucleoside monophosphate is frequently 
rate-limiting, that is the reason why the application of monophosphate prodrugs, principally 
phosphoramidates (ProTides), has been widely investigated in nucleoside analogues to avoid this 
initial phosphorylation step.26 
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The interest in the application of the ProTide technology in drug discovery has been growing 
due to the effectiveness in the in vivo intracellular delivery of nucleoside analogue 
monophosphates. In the 1980s the initial work on the ProTides had the aim of masking the oxygen 
atoms of phosphate groups in nucleoside monophosphate analogues so they are neutral at 
physiological pH and therefore have a better absorption into cells. The process took at least two 
decades to be developed and could be divided into six phases that are summarized in Table 1. 
· The first stage consisted of using alkyl and haloalkyl phosphate esters as masking groups. 
These showed great activity due to more favourable membrane-crossing ability because the 
biological activity relates to lipophilicity, rather than increased intracellular levels of the phosphate 
species. Such conclusion moved towards the upcoming strategy.  
· The second stage of nucleoside phosphate prodrugs' design was focused on alkyloxy and 
haloalkyl phosphoramidates. As a result of a non-clear structure-activity relationship from the 
haloalkyl phosphoramidates, they did not proceed any further. Nevertheless, the improvement of 
activity with nucleoside phosphoramidate prodrugs, principally with L-alanine, confirmed to be 
important for the evolution of this strategy.  
· Once proved that the use of amino acids to generate phosphoramidates led to improved 
anti-HIV activity, it was probable that the following step would be to mask both oxygen groups of 
the phosphate group by amino acid esters to obtain phoshorodiamidates.  
· In stage four, the masking groups studied in the design of a novel phosphate prodrug 
strategy were lactyl-derived systems. These were not further developed as they showed poor 
anti-HIV activity. 
· In the fifth stage, the next masking groups studied in the design of the new prodrug strategy 
were diaryl motifs but after some studies, it was concluded that the development of diaryl 
monophosphate prodrugs would not progress any further and the focus turned back to 
phosphoramidates because of their good biological activity. 
· The last stage is commonly referred to as ProTides and was inspired by the improvement of 
the biological activities of the initial examples of nucleoside monophosphate prodrugs, especially 
the aryls and the amino acid esters. McGuigan and co-workers took the next step by combining 
these two masking groups for the novel monophosphate prodrug. These prodrugs showed 
improved anti-HIV activity as compared to the parent nucleoside and the ProTide technology was 
widely pursued in the future discovery of novel antiviral and anticancer nucleotide therapeutics.27 
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Remdesivir is a prodrug based on the ProTide technology, designed to increase the efficiency 
of intracellular delivery of antiviral nucleoside analogues as monophosphoramidates. Protides are 
comprised of a nucleoside phosphoramidate of an aryl group and an amino acid ester. The 
monophosphate is masked by alkyl groups so the in vivo stability increments and the transport 
into the cells is improved. Once inside the cell, these groups are metabolically transformed into 
the active nucleoside triphosphate (NTP).27 
6.1.2. Synthesis of Remdesivir 
The route that enabled the diastereoselective synthesis of the single Sp isomer of the 
phosphoramidate prodrug is depicted in Scheme 1. The first step consisted of glycosylation and 
used the iodo-base instead of the bromo-base due to an easier metal-halogen exchange 
compatible with the isopropylmagnesium chloride lithium chloride complex (i-PrMgCl·LiCl). The 
treatment with phenylmagnesium chloride (PhMgCl) and trimethylsilyl chloride (TMSCl) granted 
the protection of the amino group before the addition of i-PrMgCl·LiCl and the ribolactone at -20ºC 
to obtain the glycosylated product. The next step consisted of cyanation and the inclusion of 
trifluoromethanesulfonic acid (TfOH) was essential to promote either high yield and selectivity 
favouring the desired β-anomer. The following step was the benzyl deprotection through 
Table 1. Stages of development of ProTide prodrugs (image taken from Mehellou, Y. et al, ref. 27). 
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treatment with boron trichloride. The penultimate step was acetonide protection of the                 
2',3'-hydroxyl moieties with 2,2-dimethoxypropane in the presence of sulphuric acid. Some 
studies demonstrated that the 2',3'-acetonide protection was optimal as the yield of coupling 
reaction with the p-nitrophenyl 2-ethylbutyl-L-alaninate phosphoramidate was highly improved 
compared to straight coupling reaction to the unprotected diol nucleoside. The last step consisted 
of two reactions, the phosphorylation and deprotection of the ribose: the prodrug was produced 
in 70% yield as a single Sp isomer. 26,28 
 
6.1.3. Mode of action of Remdesivir 
Remdesivir (GS-5734) is a prodrug metabolized within cells into an alanine metabolite        
(GS-704277), which it is further processed into the monophosphate and finally into the active 
nucleoside triphosphate derivative (see Scheme 2).   
Nucleotide analogues are not very cell-permeable, and once within the cell, they require to 
phosphorylate twice to obtain the active nucleoside triphosphate (NTP) that can be used for the 
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viral RNA-dependent RNA polymerases (RdRp) for genome replication. To avoid the 
pharmacokinetic limitations of nucleosidic drugs, phosphate and phosphonate derived 
nucleosides are usually used as prodrugs. As noted above, ProTides nucleotides are an 
optimized antiviral prodrug design in the form of phosphoramidates. 
Nucleosides are internalized into the cell through an intracellular diffusion process. The 
prodrug Remdesivir gets within the cell where it is metabolized into the nucleoside 
monophosphate via sequential hydrolytic steps that are undertaken by esterase-mediated 
hydrolysis of the amino acid ester to release a carboxylate that then cyclizes intramolecularly to 
form a cyclic anhydride ejecting the phenoxide as leaving group. Due to the instability of this cyclic 
anhydride, it is hydrolysed by water to the alanine metabolite (GS-704277) whose P-N bond is 
ultimately hydrolysed by phosphoramidases to release the nucleoside monophosphate. This 
monophosphate is highly polar and does not diffuse back through the cell membrane which 
means that it is basically confined within the cell. Then, the nucleoside monophosphate 
undertakes further phosphorylation processes by host cell kinases yielding the active NTP 
analogue form which being recognized as a substrate by the viral RNA-dependent RNA 
polymerase enzyme leads to the inhibition of this activity.8,29  
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Enzymatic experiments determined that Remdesivir-TP was a substrate for the purified EBOV 
RdRp complex and competes with ATP for incorporation as an adenosine competitor. However, 
it does not act as a chain terminator, but rather as a delayed chain terminator.30 The inhibition of 
RNA synthesis is seen predominantly at position i+5 and RNA synthesis is generally terminated 
at this point. Even if the concentration of the next nucleotide is increased, the effect does not 
overcome.31 
6.1.4. Therapeutic and pharmacological properties 
In 2014, Gilead Sciences started a clinical evaluation of Remdesivir for the Ebola virus 
(EBOV) outbreak. Nowadays, the FDA approved in May 2020 the emergency use of Remdesivir 
for the treatment of COVID-19 in adults and children hospitalized with suspected or laboratory-
confirmed Covid-19.31 Shortly after, EMA granted conditional marketing approval. In August 2020, 
Gilead Sciences has petitioned the FDA to approve its drug Remdesivir to treat COVID-19 
patients with its brand name of Veklury. The company Pfizer has reached an agreement with 
Gilead to fabricate Remdesivir. 
An article was recently published in October 2020 by Beigel, J.H. et al.28 about a randomized, 
placebo-controlled trial of intravenous Remdesivir in adults who were hospitalized with Covid-19 
and had proof of lower respiratory tract infection.  
A total of 1062 patients were randomly selected to receive either Remdesivir (200 mg loading 
dose on the first day, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 
days. Those who received Remdesivir, 541 patients in total, had a recovery time of approximately 
10 days among those who received placebo, 521 patients in total. In an analysis, they 
demonstrated that those who received Remdesivir were more likely to have clinical improvement 
at day 15 rather than the ones who received placebo. It was estimated that the percentage of 
mortality was 6.7% with Remdesivir and 11.9% with placebo by day 15 and 11.4% with 
Remdesivir and 15.2% with placebo by day 29. Also, the research group reported that serious 
adverse effects were observed in 24.6% of patients who received Remdesivir in comparison with 
31.6% of patients who received placebo.  
That study concluded that Remdesivir was better to placebo in making shorter the recovery 
time in adults who were hospitalized with Covid-19 and had proof of lower respiratory tract 
infection.  
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However, despite the use of Remdesivir, it is obvious that treatment with just an antiviral drug 
is not likely to be enough for all patients. Recent studies evaluated Remdesivir in combination 
with modifiers of the immune response, for instance, the inhibitor baricitinib. A diversity of 
therapeutic approaches such as novel antivirals, modifiers of the immune response or other 
intrinsic pathways, and mixed approaches are essential for improving outcomes in patients with 
Covid-19.32 
6.2. FAVIPIRAVIR 
Favipiravir (2, see Figure 5) was developed in 2000 and was approved for medical use in 
Japan in 2014. The drug has been proved to be strongly and selectively inhibitory against 
Influenza viruses. Additionally, Favipiravir is recognised as a novel viral RNA polymerase inhibitor. 
Thus, alike to Remdesivir, Favipiravir acts as an RNA-dependent RNA polymerase inhibitor.22 
The regularly good tolerance of human patients to Favipiravir indicate that this drug holds 
large promise for clinical use around the world. The Zhejiang Hisun Pharmaceutical company 
from China has published that Favipiravir could be a viable medication against SARS-CoV-2.14 
Appropriate doses of Favipiravir against coronaviruses are still under research. Although it is 
commonly well tolerated, the safety's knowledge of the effects with higher doses regimens is 
limited. Favipiravir can cause an increase in transaminases or diarrhoea.22 
6.2.1. Prodrug development 
Favipiravir is a pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) 
and a wide range antiviral drug approved in Japan for the treatment of Influenza viruses.24 During 
the Ebola virus outbreak initiated in West Africa during 2014, a trial with Favipiravir was carried 
out in Guinea and patients treated with the prodrug showed an improved survival trend. 
Favipiravir was first synthesized by the Japanese Chemical Company Toyama in 2000. 
However, in 2009 when Beldar et al.33 reported an optimization of the first synthetic procedure. 
Afterwards, further modifications to the synthetic route were published by different research 
groups in the following years. In 2013, Favipiravir was successfully developed by Zhang's group33 
from 3-amino-2-pyrazinecarboxylic acid with an overall yield of 22%. 
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6.2.2. Synthesis of Favipiravir 
Favipiravir was first synthesized in 2000 by a chemical route consisting of seven different 
steps14 (see Scheme 3). Starting with 3-aminopyrazine-2-carboxylic acid, the first compound was 
transformed into an ester by an esterification step using sulfuric acid and methanol. The second 
step consists of a bromination via aromatic electrophylic substitution reaction employing                 
N-bromosuccinimide in acetonitrile. The third step consisted of the conversion of 2-aminopyridine 
into 2-methoxypyridine via diazotization in methanol. Later, the 5-amination step was carried out 
by reaction with benzophenone imine was catalysed by Pd(0) in the presence of                               
(S)-(-)-2,2'-bis(diphenyl-phosphino)-1,1'-binaphthyl or (S)-BINAP. The following step consisted of 
the conversion of 3-ester into amide by using aqueous ammonia. The penultimate step was 
fluorination via diazotisation in the presence of the highly corrosive Olah reagent (HF-Py). Finally, 
an ether O-demethylation was performed by using sodium iodide and trimethylsilyl chloride. After 
these seven steps, the Favipiravir drug was created in an overall reaction yield of approximately 
0.44%. 
 
In recent years, refined methodologies for the synthesis of Favipiravir have been described. 
In particular, it was reported a four-step route14 for the synthesis of Favipiravir (see Scheme 4) 
with a higher yield compared to Scheme 3. The overall yield of Favipiravir was 8% and the route 
consisted of four steps. The starting product was the commercially available                                           
3-hydroxypyrazine-2-carboxylic acid. The initial compound was subjected to esterification and 
followed by amidation in the first step. The second step consisted of the nitration of the pyrazine 
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ring by using sulphuric acid and potassium nitrate. Once the nitration took place, the following 
step was the reduction of the nitro group by treatment with hydrazine in the presence of Raney 
nickel, which minimized the number of by-products. The last step was fluorination via diazotisation 
in the presence of HF∙pyr.  
 
Furthermore, a different route for the synthesis of Favipiravir (see Scheme 5) was developed 
by a research group from China14 through a key intermediate, the methyl                                                  
3-amino-6-bromopyrazine-2-carboxylate. According to the research group, the purity of this 
compound was determinant for the successful preparation of 3,6-dichloropyrazine-2-carbonitrile. 
In that synthesis, the starting material was 3-aminopyrazine-2-carboxylic acid and following a 
similar procedure such as in Scheme 3, it was possible to obtain the                                                            
6-bromo-3-hydroxypirazine-2-carboxamide. After that, by using phosphoryl chloride acting both 
as a dehydrating and chlorinating agent it was possible to produce the double substitution of the 
bromine and the hydroxyl with chlorine and convert also the primary amide to nitrile. The last step 
comprised the replacement of the chlorine atom with fluorine, followed by hydrolysis of the nitrile 
group obtaining the amide of Favipiravir's molecule. The overall yield was 22%. 
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A fourth procedure14 (see Scheme 6) permitted the preparation of Favipiravir from          
pyrazin-2-amine as the starting material. First, regioselective chlorination of pyrazine ring, 
followed by bromination produced 2-amino-5-chloropyrazine. After that, the next two steps were 
a regioselective 5-bromination followed by a palladium-catalyzed cyanide substitution. The fourth 
step consisted of one-pot diazotisation followed by chloride substitution to render                            
2,5-dichloropyrazine. The synthesis of the drug was completed by double nucleophilic fluorination, 
followed by nitrile hydrolysis into carboxamide and final replacement of fluorine to hydroxyl. In 
that synthesis, the overall yield of Favipiravir was 12-18%, depending on the reagents that were 
used for the first step of the route. 
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6.2.3. Mode of action of Favipiravir 
Although Favipiravir can be considered a nucleoside aglycone and is administered 
unphosphorylated, the mechanism of action34 against the virus is similar to the one for Remdesivir 
(see Figure 7).35 Favipiravir is incorporated into cells and once inside the cells, the prodrug is 
ribosylated intracellularly to form favipiravir-RMP and after two phosphorylations it is converted to 
favipiravir ribofuranosyl-5'-triphosphate, known as Favipiravir-RTP, by host cells. The nucleoside 
triphosphate form, Favipiravir-RTP, is the active metabolite which competes with purine 
nucleosides and interferes with viral replication by inclusion into the RNA virus and hence, 
potentially inhibits the activity of viral RNA dependent RNA-polymerase (RdRp).36 
 
6.2.4. Therapeutic and pharmacological properties  
A clinical trial to evaluate the efficacy and safety of Favipiravir was conducted in Shenzhen 
with the recruitment of 80 patients in a non-randomized trial. The results demonstrated a 
significant reduction in the time of viral clearance in patients treated with Favipiravir compared to 
patients treated with Lopinavir/Ritonavir, a combined antiretroviral used to treat AIDS. Thirty-five 
patients received Favipiravir 1600mg orally twice daily on day 1 followed by 600mg orally twice 
daily on days 2 to 14 and forty-five patients received the corresponding doses of 
Lopinavir/Ritonavir. The results showed a meaningful decrease in the median time to viral 
 
Figure 7. Mechanism of action of Favipiravir against the virus (image taken from Du, Y.X., Chen, X.P., ref. 36). 
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clearance with the inhibitor Favipiravir compared to Lopinavir/Ritonavir. X-ray examinations 
demonstrated a higher rate of improvement in chest imaging in the Favipiravir arm of 91.43% 
versus 62% in the Lopinavir/Ritonavir arm. Also, there was a significantly decreased rate of 
adverse effects in patients who received Favipiravir (11.4%) compared to Lopinavir/Ritonavir 
(55.6%).37,38 
Verified in vitro, Favipiravir is recognized as one likely candidate for the treatment of         
Covid-19 and preclinical animal studies on-going.39,40 The results of some ongoing randomized 
and controlled trials that study the efficacy of Favipiravir for Covid-19 will be fundamental for 
further investigation of the prodrug's role in the current coronavirus pandemic.38,41  
6.3. SINEFUNGIN 
Sinefungin (3, see Figure 5) is a natural nucleoside isolated from cultures of Streptomyces 
Griseolus and experimentally used as antibiotic. The nucleoside is structurally similar to                  
S-adenosylmethionine (SAM) and it has proved to inhibit various fungi and viruses, but its 
potential antiparasitic activity is the main current attraction.18 Sinefungin is an antibiotic that has 
important characteristics such as antiprotozoal, antifungal and antiviral properties.42,43 The natural 
nucleoside inhibits transmethylation reactions related to RNA, proteins, DNA and other molecules.  
Very recently, Sinefungin was also found to be an effective nsp16 MTase inhibitor against 
MERS-CoV and SARS-CoV. However, the inhibitory activity of SFG towards SARS-CoV-2 
nsp16/nsp10 MTase need further investigation for their potential for treating Covid-19.44,45  
6.3.1. Drug development 
The isolation of the antibiotic was reported from cultures of Streptomyces griseolus and 
Streptomyces incarnatus at Lilly Research Laboratories in 1971. The inhibitory effect of the drug 
was studied on some S-adenosylmethionine mediated transmethylation reactions in cell culture 
and in vivo due to structural similarity to analogues S-adenosylmethionine (SAM) and                       
S-adenosylhomocysteine (SAH).46 
 6.3.2. Synthesis of Sinefungin 
Sinefungin was first synthesized by Mock and co-workers47 in 1982 and the C6' stereocenter 
was the main synthetic challenge. The product was obtained as a mixture of C6'-epimers that 
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could be separable by chromatographic methods or through stereoselective transformations such 
as the alkylation of a chiral imide auxiliary by Ghosh team or the diastereoselective reduction of 
a ketone at C6' by Rapoport and co-workers.47 In every case, it was necessary to interconvert 
multiple functional groups to elaborate the alkyl chain of the natural nucleoside molecule, limiting 
the tractability of these approaches for the effective synthesis of Sinefungin and its potential 
analogues.47 
The promising use of Sinefungin and the structurally related analogues to target                   
SAM-dependent methyltransferases inspired for the synthesis of C9'-epi-sinefungin47 (see 
Scheme 7). A study provided a satisfactory solution to the obtention of the key C6' amine of the 
drug scaffold, which can be applied to the synthesis of new analogues of Sinefungin in order to 
investigate new MT inhibitors. 
The synthesis of C9'-epi-sinefungin had as a starting material acetonide 6, which is 
commercially available or easily accessible from D-ribose. Triflation of acetonide, followed by 
alkynylation upon treatment with lithium acetylide generated the silyl-protected propargyl alcohol 
7. Next step consisted of the cleavage of the TBS protecting group and subsequent reduction to 
the (E)- allylic alcohol 8 with lithium aluminium hydride. The following step converted the alcohol 
8 to trichloroacetimidate 9 in the presence of trichloroacetonitrile obtaining the required precursor 
for the envisioned Overman rearrangement.  
The treatment of (E)-allylic trichloroacetimidate 9 in dichloromethane with Overman's catalyst 
resulted with the desired [3,3]-sigmatropic rearrangement producing allylic trichloroacetamide 10 
as the major diastereomer which could be isolated by chromatography. The catalytic 
diastereoselective rearrangement provided an efficient solution to the installation of the 
stereocenter at C6'.  
Once the stereocenter at C6' was build, the next steps consisted of the elaboration of the 
amino acid moiety. The terminal alkene 10 was oxidated to aldehyde 11 and followed a        
Horner-Wadsworth-Emmons olefination that produced the enamide 12. The C9' amino 
stereocenter was set by asymmetric hydrogenation with (S,S)-Ph-BPE-Rh catalyst, that provided 
(R)-carbamate 13 as a single diastereoisomer.  
Once the C5'-C10' amino acid chain was elaborated, the addition of the adenine moiety and 
succeeding global deprotection were undertaken. The acetonide 13 was converted in two steps 
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into triacetate 14 and after that, Vorbrüggen glycosylation supported by                                                 
2,6-di-tert-butyl-4-methylpyridinium triflate synthesized the trichloroacetamide nucleoside 15 as a 
single diastereomer.  
The final two steps involve the removal of various protecting groups. The importance of adding 
certain conditions which would selectively deprotect the C6' amine over the C9' one, was of 
potential interest because of its practical way for the synthesis of Sinefungin analogues at this 
position. The penultimate step was the treatment of the nucleoside 15 with aqueous potassium 
hydroxide that delivered the amine 16 in good yield, leaving intact the C9'-Cbz-protected amine. 
The final step was the cleavage of the other protecting group, Cbz, by hydrogenolysis and removal 
of the Bz protecting group with methanolic ammonia that ended in the obtention of                          
C9'-epi-sinefungin 17. That route synthetic comprised a total of 11 steps with an overall yield of 
7.6%.47,48  
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6.3.3. Mode of action of Sinefungin 
Structural similarity between analogues with the natural nsp16 co-substrate SAM revealed 
that analogues that operate as competitive binders of SAM might be effective inhibitors of              
2’-O-MTase catalytic activity.49 The nsp16 protein from SARS-CoV-2 is a SAM-dependent 
(nucleoside-2'-O)-methyltransferase (2'-O-MTase) that its activity is regulated by nsp10 allosteric 
activator. The nsp16 protein catalyzes the methyl transfer from SAM to Cap-0, generating the 
products SAH and Cap-1. This transmethylation can be inhibited by Sinefungin, an analogue of 
SAH used as a pan-inhibitor of MTases.50  
Based on early research, recent crystallographic studies showed that MTase inhibitors like 
Sinefungin adhered to SAM binding site and could suppress coronaviral MTase activity of 
nsp16.51,52  
6.3.4. Therapeutic and pharmacological properties 
Some studies showed that Sinefungin exhibited a variety of biological effects including the 
inhibition of diverse fungi's growth, virus replication and antiparasitic effects in vivo and in vitro. 
Despite these meaningful biological activities for antiviral research, Sinefungin has limited use as 
an antibiotic because of its nephrotoxicity that induces bone marrow depression in laboratory 
animals.53 
Further studies will be required to review and analyse if Sinefungin could be a potential 
inhibitor of nsp16 MTase of earlier MERS-CoV and SARS-CoV.
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7. CONCLUSIONS 
The rapid spread of the novel beta coronavirus SARS-CoV-2, first reported in Wuhan in 
December 2019 due to high human-to-human transmission, along with the inability to stop the 
pandemic, is causing a high mortality and the paralysation of world's economy.  
The scientific community from all over the world has been working together to fight against 
SARS-CoV-2. Although some vaccines have been recently approved and some countries like the 
UK or Spain started a massive vaccination, the repositioning of available drugs could be also an 
essential strategy in the development of novel drugs. Within this aim, Remdesivir, Favipiravir or 
Sinefungin are currently studied at different stages to determine their antiviral potential against 
SARS-CoV-2 although more studies will be required to comprehensively understand their antiviral 
potential. 
Remdesivir and Favipiravir are prodrugs and potent inhibitors of viral RNA-dependent RNA 
polymerase (RdRp). Both prodrugs have been studied for other outbreaks because of their 
multiple RNA viruses’ inhibitions. Remdesivir is currently under evaluation for COVID-19 and it is 
considered the most promising antiviral drug. That is the main reason why a large-scale study 
investigating the clinical efficacy of Remdesivir is on-going. Favipiravir, known as an anti-influenza 
RdRp, also started being clinically investigated for its effectiveness in COVID-19 patients.  
Sinefungin, a bacterial metabolite, is a novel drug that inhibits the activity of viral MTases. 
Due to nephrotoxicity, it will require further investigation and therapeutic trials to establish whether 
the drug is indeed effective against SARS-CoV-2. 
Drug repurposing is possibly a crucial and global strategy for novel drugs' development for 
the treatment of emerging diseases such as COVID-19 because of its key benefits such as limited 
clinical trials, especially concerning phases I and II, and the opportunity for improving and 
discovering new types of medicines from the early drugs with higher efficacy and safety profiles. 
Unfortunately, outbreaks of CoV or other viruses are likely to happen in the coming years, 
that is the principal reason why we, as a society, need to adapt our lives to the new normality. As 
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a future projection, further clinical and therapeutic investigations will be essential to prevent and 
treat future viruses to avoid pandemics like the current one.  
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9. ACRONYMS AND ABBREVIATIONS 
ACE2 – Angiotensin-converting enzyme 2 
AEMP – Agencia Española de Medicamentos y Productos Sanitarios 
BPE – bis(phospholano)-ethane 
BSA (Favipiravir) – N-chloro-N-methoxybenzenesulfonamide 
BSA – N,O-bis(trimethylsilyl)acetamide 
COP – Cobalt Oxazoline Palladacycle 
CoV – Coronavirus 
COVID-19 – Coronavirus Disease 2019 
DIEA – Diisopropylethylamine (Hunig’s Base) 
DTBMP-OTf – 2,6-di-tert-butyl-4-methylpyridinium triflate 
EMA – European Medicines Agency 
FDA – American Food and Drug Administration 
GS-5734 – Gilead Sciences 5734 (Remdesivir’s investigational name) 
H – Helicase 
MERS – Middle East Respiratory Syndrome 
MERS-CoV – Middle East Respiratory Syndrome Coronavirus 
MTase – 2’-O-RNA Methyl Transferase  
nbd - norbornadiene 
NTP – Nucleoside Triphosphate 
Plpro – Papain-like protease 
RBD – Receptor-binding domain 
RdRp – RNA-dependent RNA polymerase 
SAM – S-adenosylmethionine 
44 Pruñonosa Martin, Laia 
 
SARS – Severe Acute Respiratoy Syndrome  
SARS-CoV – Severe Acute Respiratoy Syndrome Coronavirus 
SARS-CoV-2 – Severe Acute Respiratory Syndrome Coronavirus 2 
TMG – 1,1,3,3-tetramethylguanidine 
TMPRSS2 – Transmembrane protease, serine 2 
TSA - N-chloro-N-methoxy-4-methylbenzenesulfonamide 
3CLpro – 3-chymotrypsin-like protease 
 
 
 
 
